MCM
IBB icon

Mainstream Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Mainstream Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+1,076
New +$185K 0.12% 89
2025
Q1 		– Sell
-1,132
Closed -$150K – 176
2024
Q4 		$150K Buy
+1,132
New +$159K 0.1% 96

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Mainstream Capital Management's IBB Position: Q2 2026 in Review

Mainstream Capital Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,076 shares worth $205K. The stake represents 0.12% of the portfolio and ranks #89 among its holdings. This is a return to the name: Mainstream Capital Management previously reported a position in IBB as recently as Q4 2024.

Mainstream Capital Management first reported a position in IBB in Q4 2024 and has held it in 2 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Mainstream Capital Management held 1,076 shares of iShares Biotechnology ETF worth $205K as of Q2 2026.
  • iShares Biotechnology ETF was a new Mainstream Capital Management position in Q2 2026.
  • iShares Biotechnology ETF made up 0.12% of Mainstream Capital Management's portfolio in Q2 2026, its #89 holding.
  • Mainstream Capital Management first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 2 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Mainstream Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.